SAN DIEGO � October 18, 2011 (Investorideas.com newswire) – Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will begin accepting orders for its Enzyme Linked Lectin Specific Assay (ELLSA™) from researchers that require a highly sensitive diagnostic tool to detect the ...
The post Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces Availability of its Exosome Detection Assay to the Research Community appeared first on Your Story.